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Purpose or Objective: In order to evaluate the usefulness of 
high-dose-rate interstitial brachytherapy (HDR-ISBT) as 
monotherapy for locally limited mobile tongue cancer, we 
analyzed our clinical experience. 
 
Material and Methods: We investigated 29 locally limited 
mobile tongue cancer treated by HDR-ISBT as monotherapy at 
National Hospital Organization Osaka National Hospital 
between February 2001 and August 2012. The median age of 
the patients was 60 years (range: 34–84 years). All patients 
had histologically confirmed squamous cell carcinoma. 
According to the UICC classification of 2007, 3 T1, 18 T2 and 
8 T3 were classified, respectively. The median tumor 
thickness of the patients was 10 mm (range: 2–45 mm). Ten 
(34%) medically poor risk patients (more than 80 years of age 
or severe intercurrent disease) were included. One patient 
had previous irradiation history. All but one patients received 
54 Gy in 9 fractions. The other patient reduced his treatment 
doses (48 Gy in 8 fractions) because of previous irradiation 
history. We used three-dimensional planning for later 7 
patients and delivered the prescribed doses to CTV (clinical 
target volume). Gross tumor volume (GTV) was defined with 
metal markers positions, applicator positions, intraoral 
ultrasonography and CT image. The GTV was equal to the 
CTV. 
 
Results: The median follow-up time was 47 months (range; 
10-171 months). The median V100(CTV) were 100%prescribed 
dose (range; 99.6-100%) for 7 evaluable patients. The 4-year 
local control rates were 100%, 73% and 88% for T1, T2 and T3. 
The 4-year overall survival rates were 67%, 66% and 31% for 
T1, T2 and T3. The 4-year local control rates were 88%, 83% 
and 60% for tumor thickness of <10 mm (12 patients), 10-19 
mm (12 patients) and ≥20 mm (5 patients). The 4-year overall 
survival rates were 63%, 67% and 40% for tumor thickness of 
<10 mm, 10-19 mm and ≥20 mm. Four (14%) patients showed 
moderate to severe radiation ulcer.  
 
Conclusion: Our treatment result of HDR-ISBT as 
monotherapy showed good local control result although there 
were many medically poor risk patients. Overall survival rate 
was worse for patients who had T3 tumor or tumor thickness 
of ≥20 mm. 
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Purpose or Objective: To evaluate the efficacy and safety of 
interstitial permanent low dose rate 125I seeds implantation 
under ultrasound guidance for local recurrent tumor of head 
and neck. 
 
Material and Methods: A total of 70 patients (median age, 
60years; range, 4–94 years) with malignant mass in head and 
neck were retrospectivel -y studyed ( from Jan. 2004 to Oct. 
2014). 6 were lost to follow-up, and 64 met the inclusion 
criteria. 81 lesions in head and neck implanted 125I seeds 
were evaluated. And 54 of 81 lesions were diagnosed cervical 
lymph node recurrence and another 27 lesions were local 
recurrence of primary or residual after first management. All 
the patient underwent 125I seed implantation guided by 
ultrasonography (Color Doppler Ultrasound with high 
frequency probe and guiding stabilization devices, Alokaα-10, 
Figure 1) with adequate local anesthesia. Postoperative 
dosimetry was routinely performed by TPS (3D treatment 
planning system; Beijing Fei Tian Industries, Inc.) for all 
patients. The actuarial D90 of the implanted 125 I seeds 
ranged from 100Gy to 160Gy (median:130Gy). The activity of 
125 I seeds ranged from 0.3mCi to 0.8mCi (median: 0.69mCi). 
The total number of seeds implanted ranged from 3 to 89 
(median: 20). The follow-up period ranged from1 to103.5 
months (median: 14months).The survival and local control 
probabilities were calculated by the Kaplan-Meier method 
(SPSS 16.0). 
 
Results: Among all the 81 lesions, totally response rate was 
80.2% , 22 lesions had complete remission CR (27%) and 43 
had partial remission PR (53%) . The 1- ,3-and 5-year tumor 
control rates were all 75.2% , 73% and 69.1%respectively. The 
results of cervical lymph node recurrence shows better than 
the recurrence or residue of primary head and neck 
neoplasm, with the local control of 5 year was 72.7% and 
39.9% respectively. As of the date of follow-up, 22 of 64 
patients still alive , The 1- and 3-,5-year overall survival 
rates were 57.4% , 31%, 26.6% respectively, with a median 
survival of 20 months. Grade 4 side effects of skin ulceration 
was seen in 2 patient; grade 1 or 2 skin reactions were seen 
in 11 patients (17%) who had received external beam 





Conclusion: Interstitial permanent implantation of 125 I 
seeds under ultrasound guidance is feasible, efficacious and 
safe for refractory head and neck metastasis or recurrence. 
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Purpose or Objective: A new methodology using magnetic 
resonance (MR) imaging for brachytherapy dose planning of 
esophageal cancer has been developed. The main objective 
